Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 03, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,422.99 pence per share.
- Treasury Holdings Post-Transaction: 186,681,678 shares.
- Shares in Issue (excluding Treasury): 5,797,625,434 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 1,400,000 shares for Treasury. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 1,400,000 share repurchase based on the disclosed price of 1,422.99 pence.
- Confirm the updated total share capital structure (5,797,625,434 shares in issue plus 186,681,678 Treasury shares).
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.